Why It Matters
The American College of Clinical Pharmacy filed its second quarter lobbying disclosure Aug. 7, reporting $450,000 in spending. The organization has maintained consistent quarterly expenditures across multiple disclosure filings, with the same amount reported for quarter three 2025, quarter four 2025, quarter one 2026, and now quarter two 2026.
The organization lobbied on two core issues in the second quarter: Medicare and Medicaid recognition and coverage for clinical pharmacy services, and graduate-level pharmacy training and education.
By the Numbers
The American College of Clinical Pharmacy is split between in-house lobbying and external representation. The organization filed four in-house lobbying reports over the past year, averaging $144,981 per quarter. It also filed four reports through Capitol Advocacy & Government Affairs LLC, averaging $450,000 per quarter.
Paul Kelly of Capitol Advocacy & Government Affairs LLC served as the external lobbyist for the organization in quarter two 2026.
Broader Context
Relevant federal legislation may align with the organization's lobbying priorities. The Right Drug Dose Now Act, introduced by Rep. Dan Crenshaw (R-TX-2) aims to update the National Action Plan for Adverse Drug Event Prevention by integrating advancements in pharmacogenomic research and testing. The American College of Clinical Pharmacy publically supports this legislation.
The organization's focus on Medicare pharmacy coverage relates to broader congressional discussions about healthcare payment models. A Congressional Research Service report on Medicare Graduate Medical Education was issued in August 2025.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article